Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Non-Current Deffered Revenue (2022 - 2024)

NewAmsterdam Pharma's Non-Current Deffered Revenue history spans 3 years, with the latest figure at $222000.0 for Q2 2024.

  • For Q2 2024, Non-Current Deffered Revenue changed N/A year-over-year to $222000.0; the TTM value through Jun 2024 reached $222000.0, changed N/A, while the annual FY2023 figure was $1.0 million, 78.74% down from the prior year.
  • Non-Current Deffered Revenue for Q2 2024 was $222000.0 at NewAmsterdam Pharma, down from $444000.0 in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $4.6 million in Q4 2022 and bottomed at $222000.0 in Q2 2024.
  • The 3-year median for Non-Current Deffered Revenue is $731500.0 (2023), against an average of $1.6 million.
  • The largest YoY upside for Non-Current Deffered Revenue was 77.77% in 2023 against a maximum downside of 77.77% in 2023.
  • A 3-year view of Non-Current Deffered Revenue shows it stood at $4.6 million in 2022, then plummeted by 77.77% to $1.0 million in 2023, then crashed by 78.21% to $222000.0 in 2024.
  • Per Business Quant, the three most recent readings for NAMS's Non-Current Deffered Revenue are $222000.0 (Q2 2024), $444000.0 (Q1 2024), and $1.0 million (Q4 2023).